AIVITA Biomedical to Present at Biotech Showcase 2019

Date: Jan 03, 2019

IRVINE, Calif. – January 3, 2019 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that it will be featured as a presenting company at the annual Biotech Showcase™ conference taking place January 7-9 at the Hilton San Francisco Union Square in San Francisco, California. Dr. Hans S. Keirstead, AIVITA’s Chairman and CEO, will present at the following time and location:

Date: Wednesday, January 9, 2019
Time: 10:45 AM
Track: Franciscan C (Ballroom Level)

Biotech Showcase™ is an annual investor and networking conference that provides private and public biotechnology and life science companies with an opportunity to present and meet with investors and pharmaceutical executives.

Dr. Keirstead will be presenting details on AIVITA’s platform cancer technology, a next generation immunotherapy targeting the tumor-initiating stem cell, with strong clinical data evidencing 72% survival at 2-years, and 54% survival at 5-years post-treatment. AIVITA’s ROOT OF CANCER technology is the subject of two ongoing Phase 2 trials in the USA, one in patients with advanced ovarian cancer and another in patients with newly diagnosed glioblastoma. AIVITA’s ROOT OF CANCER technology is also under review for conditional commercialization approval by Japan’s PMDA to treat melanoma.

AIVITA executives will also be attending the coinciding J.P. Morgan Healthcare Conference, taking place January 7-10 at the Westin St. Francis Hotel in San Francisco. To schedule a meeting with AIVITA, investors can send a request to:

Contact:
Kevin Green
Vice President, Business Development
direct: 949-872-2555 x113
e-mail: kevin[at]aivitabiomedical.com

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA’s skin care products support the treatment of women with ovarian cancer.

###